Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance ...
NDA Preparation Strategy 2026: NDA 1 2026 exam is scheduled for April 12, 2026. With only a few months left, candidates should start preparing for the exam. Begin by reviewing the latest syllabus and ...
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Hosted on MSN
Vistagen targets NDA submission for fasedienol in mid-2026 as PALISADE-3 study nears data readout
President and CEO Shawn Singh announced "another major milestone in our PALISADE program. The last patient completed the randomized double-blind portion of our PALISADE-3 Phase III trial, evaluating ...
CEO Rick Stewart stated that "Achieve is on track to submit the NDA for cytisinicline next month." He emphasized that "all internal resources are now focused on a successful NDA submission, acceptance ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results